Evidence map›Paper›PMID 36947045›Full record

ArticleJAMA psychiatry2023

Association Between Retinal Features From Multimodal Imaging and Schizophrenia.

Siegfried K Wagner, Mario Cortina-Borja, Steven M Silverstein, Yukun Zhou, David Romero-Bascones, Robbert R Struyven, Emanuele Trucco, Muthu R K Mookiah, Tom MacGillivray, Stephen Hogg and 12 more

Abstract read
In one paragraph

Article in JAMA psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Siegfried K WagnerNIHR Moorfields Biomedical Research Centre, London, United Kingdom.
Mario Cortina-BorjaGreat Ormond Street Institute of Child Health, University College London, London, United Kingdom.
Steven M SilversteinDepartment of Psychiatry, University of Rochester Medical Center, Rochester, New York.
Yukun ZhouNIHR Moorfields Biomedical Research Centre, London, United Kingdom.
David Romero-BasconesMoorfields Eye Hospital NHS Foundation Trust, London, United Kingdom.
Robbert R StruyvenNIHR Moorfields Biomedical Research Centre, London, United Kingdom.
Emanuele TruccoVAMPIRE Project, School of Science and Engineering, University of Dundee, Dundee, United Kingdom.
Muthu R K MookiahVAMPIRE Project, School of Science and Engineering, University of Dundee, Dundee, United Kingdom.
Tom MacGillivrayVAMPIRE Project, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.
Stephen HoggVAMPIRE Project, School of Science and Engineering, University of Dundee, Dundee, United Kingdom.
Timing LiuMoorfields Eye Hospital NHS Foundation Trust, London, United Kingdom.
Dominic J WilliamsonNIHR Moorfields Biomedical Research Centre, London, United Kingdom.
Nikolas PontikosNIHR Moorfields Biomedical Research Centre, London, United Kingdom.
Praveen J PatelNIHR Moorfields Biomedical Research Centre, London, United Kingdom.
Konstantinos BalaskasNIHR Moorfields Biomedical Research Centre, London, United Kingdom.
Daniel C AlexanderCentre for Medical Image Computing, Department of Computer Science, University College London, London, United Kingdom.
Kelsey V StuartNIHR Moorfields Biomedical Research Centre, London, United Kingdom.
Anthony P KhawajaNIHR Moorfields Biomedical Research Centre, London, United Kingdom.
Alastair K DennistonUniversity of Birmingham, Birmingham, United Kingdom.
Jugnoo S RahiNIHR Moorfields Biomedical Research Centre, London, United Kingdom.
Axel PetzoldNIHR Moorfields Biomedical Research Centre, London, United Kingdom.
Pearse A KeaneNIHR Moorfields Biomedical Research Centre, London, United Kingdom.

Funding

Department of HealthMedical Research Council MC_PC_19005Medical Research Council MR/T000953/1Medical Research Council MR/T019050/1Medical Research Council MR/T040912/1
6 · The paper itself

Abstract

Importance: The potential association of schizophrenia with distinct retinal changes is of clinical interest but has been challenging to investigate because of a lack of sufficiently large and detailed cohorts. Objective: To investigate the association between retinal biomarkers from multimodal imaging (oculomics) and schizophrenia in a large real-world population. Design, Setting, and Participants: This cross-sectional analysis used data from a retrospective cohort of 154 830 patients 40 years and older from the AlzEye study, which linked ophthalmic data with hospital admission data across England. Patients attended Moorfields Eye Hospital, a secondary care ophthalmic hospital with a principal central site, 4 district hubs, and 5 satellite clinics in and around London, United Kingdom, and had retinal imaging during the study period (January 2008 and April 2018). Data were analyzed from January 2022 to July 2022. Main Outcomes and Measures: Retinovascular and optic nerve indices were computed from color fundus photography. Macular retinal nerve fiber layer (RNFL) and ganglion cell-inner plexiform layer (mGC-IPL) thicknesses were extracted from optical coherence tomography. Linear mixed-effects models were used to examine the association between schizophrenia and retinal biomarkers. Results: A total of 485 individuals (747 eyes) with schizophrenia (mean [SD] age, 64.9 years [12.2]; 258 [53.2%] female) and 100 931 individuals (165 400 eyes) without schizophrenia (mean age, 65.9 years [13.7]; 53 253 [52.8%] female) were included after images underwent quality control and potentially confounding conditions were excluded. Individuals with schizophrenia were more likely to have hypertension (407 [83.9%] vs 49 971 [48.0%]) and diabetes (364 [75.1%] vs 28 762 [27.6%]). The schizophrenia group had thinner mGC-IPL (-4.05 μm, 95% CI, -5.40 to -2.69; P = 5.4 × 10-9), which persisted when investigating only patients without diabetes (-3.99 μm; 95% CI, -6.67 to -1.30; P = .004) or just those 55 years and younger (-2.90 μm; 95% CI, -5.55 to -0.24; P = .03). On adjusted analysis, retinal fractal dimension among vascular variables was reduced in individuals with schizophrenia (-0.14 units; 95% CI, -0.22 to -0.05; P = .001), although this was not present when excluding patients with diabetes. Conclusions and Relevance: In this study, patients with schizophrenia had measurable differences in neural and vascular integrity of the retina. Differences in retinal vasculature were mostly secondary to the higher prevalence of diabetes and hypertension in patients with schizophrenia. The role of retinal features as adjunct outcomes in patients with schizophrenia warrants further investigation.

Indexed as

HypertensionSchizophreniaAgedCross-Sectional StudiesFemaleHumansMaleMiddle AgedMultimodal ImagingRetinaRetinal Ganglion CellsRetrospective StudiesTomography, Optical Coherence

Identifiers

PMID36947045
PMCPMC10034669

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.